Anti-cancer agents and androgen inhibition activity compound
First Claim
1. A method for inhibiting androgen activity in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprisingan androgen inhibition activity compound of structure (1);
- anda pharmaceutically acceptable carrier, diluent or excipient,
2 Assignments
0 Petitions
Accused Products
Abstract
A qualitative 3D pharmacophore model (a common feature based model or Catalyst HipHop algorithm) developed from well-known natural product androgen receptor down-regulating agents (ARDAs). The 3D pharmacophore model is used as a template in virtual screening compounds for new ARDAs. ARDA compounds and compounds that strongly inhibit the growth of human prostate LNCaP cells. The compounds may be used in compositions and methods of inhibiting cell proliferation of a cancer and methods of preventing or treating cancer, including prostate cancer.
10 Citations
7 Claims
-
1. A method for inhibiting androgen activity in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising
an androgen inhibition activity compound of structure (1); - and
a pharmaceutically acceptable carrier, diluent or excipient, - View Dependent Claims (3, 4, 5, 6, 7)
- and
-
2. A method for inhibiting androgen activity in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising an androgen inhibition activity compound is selected from the group consisting of [(4-Methylphenyl)sulfonyl](2-nitrophenyl)amine, (2-Nitrophenyl)(phenylsulfonyl)amine, (4-Methyl-2-nitrophenyl)(phenylsulfonyl)amine, [(4-Fluorophenyl)sulfonyl](4-methyl-2-nitrophenyl)amine, 5-Methyl-2-[(phenylsulfonyl)amino]benzoic acid, and [(4-Methylphenyl)[(4-methylphenyl)sulfonyl]amine.
Specification